Výsledky vyhledávání - "Guillermo Alonso-Jaudenes Curbera"

Akademický článek

Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain

Autor: Guillermo Alonso-Jáudenes Curbera, Martín Igor Gómez-Randulfe Rodríguez, Beatriz Alonso de Castro, Sofía Silva Díaz, Iria Parajó Vázquez, Paula Gratal, Rafael López López, Rosario García Campelo

Publikováno v: BMJ Open Quality, Vol 13, Iss 2 (2024)

Background Evaluation of quality of care in oncology is key in ensuring patients receive adequate treatment. American Society of Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI) Certification Program (QCP) is an international

Externí odkaz: https://doaj.org/article/cfeaa1f871a1442ba80bbd2b5047f07b

Zobrazit plný text záznamu

Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

Publikováno v: Journal of geriatric oncology. 12(3)

Background Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line of treatment. Older patients are often not represented in clinical trials and dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc8f0359c9eb9f002de01c36c87004c8
https://pubmed.ncbi.nlm.nih.gov/33357975

Zobrazit plný text záznamu

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience

Publikováno v: Translational Lung Cancer Research. 7:404-415

Background Recently, immunotherapy has changed the standard of treatment in non-small cell lung cancer (NSCLC). Outside clinical trials, data of real life is lacking. This is an observational study that represents the real world experience with nivol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0cc7bb30d30b4aba37c3cf312d55b53a
https://doi.org/10.21037/tlcr.2018.04.03

Zobrazit plný text záznamu

Utility of the Lung Immune Prognostic Index (LIPI) in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab

Publikováno v: Journal of Clinical Oncology. 37:e20645-e20645

e20645 Background: The lung immune prognostic index (LIPI) has been proposed as a new biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 or programmed death ligand 1 therapy. In this study, we in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aa744ffa139bdae4677d0bc712ca0139
https://doi.org/10.1200/jco.2019.37.15_suppl.e20645

Zobrazit plný text záznamu

BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p)

Publikováno v: Journal of Clinical Oncology. 33:e19078-e19078

e19078 Background: EGFR mutations are among the most common driver mutations, responding well, albeit transiently, to EGFR TKIs. We were able to identify high levels of BIM mRNA expression as a predictive marker of response, progression free survival

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8087e89184b8d0b150d6563c30e9d5c2
https://doi.org/10.1200/jco.2015.33.15_suppl.e19078

Zobrazit plný text záznamu

Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL)

Autor: Margarita Majem, Juan Luis Marti-Ciriquian, Miguel Angel Molina-Vila, Rosario Garcia Campelo, Pablo Martinez, Enriqueta Felip, Felipe Cardenal, Cinta Pallares, Guillermo Alonso-Jaudenes Curbera, Clara Mayo de las Casas, Maria Carmen Gonzalez-Arenas, Ramon Palmero, Rafael Rosell, Enric Carcereny Costa, Bartomeu Massuti, Maria Sanchez-Ronco

Publikováno v: Journal of Clinical Oncology. 32:8079-8079

8079 Background: Progression-free survival (PFS) and response rate (RR) to EGFR tyrosine kinase inhibitors (TKIs) vary in P with NSCLC driven by EGFR mutations, suggesting that other genetic alterations may influence oncogene addiction. High BRCA1 mR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51f7b65d7d4ff0b73c9c2e021042372a
https://doi.org/10.1200/jco.2014.32.15_suppl.8079

Zobrazit plný text záznamu

Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL)

Autor: Bartomeu Massuti, Clara Mayo de las Casas, Miguel Angel Molina-Vila, Margarita Majem, Guillermo Alonso-Jaudenes Curbera, Maria Carmen Gonzalez-Arenas, Ramon Palmero, Felipe Cardenal, Juan Luis Marti-Ciriquian, Rafael Rosell, Rosario Garcia Campelo, Maria Sanchez-Ronco, Alex Martinez Marti, Cinta Pallares, Enric Carcereny, Enriqueta Felip

Publikováno v: Journal of Clinical Oncology. 31:2581-2581

2581 Background: Progression-free survival (PFS) and response to EGFR tyrosine kinase inhibitors (TKIs) vary in p with NSCLC driven by EGFR mutations. In our experience, high BRCA1 mRNA expression was associated with shorter PFS in EGFR-mutant p trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af3b6dd96d4d3d8d549a06ae58e206b6
https://doi.org/10.1200/jco.2013.31.15_suppl.2581

Zobrazit plný text záznamu

MicroRNAs and response to anti-EGFR therapy in metastatic colorectal cancer

Autor: Francisco Arnal, Moisés Blanco-Calvo, Vanessa Medina Villaamil, Angélica Figueroa, Margarita Reboredo, Mar Haz-Conde, Guillermo Alonso-Jaudenes Curbera, Maria J. Lorenzo-Patiño, Manuel Valladares-Ayerbes, Luis M. Antón-Aparicio, Teresa Rodríguez-Rigueiro

Publikováno v: Journal of Clinical Oncology. 30:e21002-e21002

e21002 Background: The discovery of KRAS gene as response predictive factor to anti-EGFR antibodies supposed a revolution in the pharmacological management of metastatic colorectal cancer (mCRC) patients (pts), since only KRAS native (WT) pts are pos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::26f4e6eb765468b9008b2155369aa3e8
https://doi.org/10.1200/jco.2012.30.15_suppl.e21002

Zobrazit plný text záznamu

Circulating microRNAs as potential biomarkers in patients with renal tumors

Autor: Manuel Valladares Ayerbes, Luis M. Antón Aparicio, Maria Quindós Varela, Guadalupe Aparicio Gallego, Isabel Santamarina, Vanessa Medina, Silvia Díaz Prado, Guillermo Alonso-Jaudenes Curbera

Publikováno v: Journal of Clinical Oncology. 30:405-405

405 Background: MicroRNAs (miRNAs), a class of small RNAs, have been intensely investigated recently because of their important regulatory role in gene expression. Circulating miARNs are potential biomarkers for cancer not only abundant in blood, but

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::431d9388635f469f8572bc6a699a6d0e
https://doi.org/10.1200/jco.2012.30.5_suppl.405

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání